earnings
confidence high
sentiment positive
materiality 0.75
Ardelyx reports 2025 revenue $407.3M; IBSRELA up 73% to $274.2M; guides 2026 higher
ARDELYX, INC.
2025-FY EPS reported
-$0.26
revenue$407,320,000
- IBSRELA revenue $274.2M in 2025 (+73% YoY); Q4 $86.6M (+61% YoY).
- XPHOZAH revenue $103.6M in 2025; 2026 guidance $110-120M.
- Total 2025 revenue $407.3M; net loss $61.6M ($0.26 loss per share).
- Cash $264.7M at Dec 31, 2025; fully capitalised for current plans.
- Phase 3 ACCEL trial for tenapanor in CIC dosed first patient; topline H2 2027.